Efficacy and Safety of Topical Calcipotriol 0.005 Versus Topical Clobetasol 0.05 in the Management of Alopecia Areata: An Intrasubject Pilot Study

摘要

The study conformed with the Helsinki Declaration of 1964, as revised in 2013, concerning human and animal rights. Ethics committee approval was not required as all patients were treated with effective topical therapies (the use of AA calcipotriol appears to be supported by data in the literature) and calcipotriol is already successfully used in our clinical practice in the treatment of AA of the beard. Informed consent was obtained for each participant.